TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER WITH PEMBROLIZUMAB: AN INTEGRATIVE REVIEW

UMA REVISÃO INTEGRATIVA

Authors

DOI:

https://doi.org/10.61229/mpj.v2i2.65

Abstract

Introduction: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of estrogen, progesterone, and HER2 receptors. This molecular profile restricts treatment options, positioning chemotherapy as the primary therapeutic approach. TNBC is more prevalent among young women and is frequently associated with BRCA1 gene mutations. Pembrolizumab, a monoclonal antibody targeting the PD-1 pathway, enhances the immune response by enabling T lymphocytes to recognize and destroy tumor cells. Objective: To investigate immunotherapeutic strategies for the treatment of TNBC, with a focus on pembrolizumab as a potential alternative to conventional therapies, aiming to improve patient outcomes and quality of life. Methods: This two-phase study involved: (1) an integrative literature review using the descriptors “Neoplasms,” “Therapy,” and “Hospitalized Children,” selecting full-text Portuguese articles published within the last eight years; and (2) the development of a therapeutic comic book (CET). Results: Ten studies were included and thematically categorized into: general chemotherapy principles, most prevalent side effects in pediatric oncology patients, and recommended physical and emotional care strategies. The CET was divided into two parts: the first narrates the story of “Super Action,” a hero character illustrating cancer, chemotherapy, and side effects in a child-friendly manner; the second outlines essential supportive care during treatment. Conclusion: The comic book is a supportive intervention aimed at improving the quality of life of pediatric oncology patients. It facilitates better understanding of cancer and chemotherapy, encourages treatment adherence, and promotes a positive self-image and family involvement.

Downloads

Download data is not yet available.

Author Biographies

Aline Ferreira, Universidade Prof, Edson Antonio Velano

I am a Biomedicine undergraduate student at Professor Edson Antonio Velano University, currently in the 7th semester of the course. I am interested in the areas of imaging diagnosis, clinical analysis and biomedical research, with a focus on the application of imaging technologies in the detection and monitoring of diseases. During my undergraduate studies, I have been developing skills in laboratory techniques and deepening my studies on methods such as magnetic resonance imaging, computed tomography and ultrasound. I have participated in practical activities and extension projects that have contributed to the construction of a solid theoretical basis and the improvement of technical skills. I seek to integrate scientific knowledge with technological advances, aiming to contribute to the development of more accurate and effective diagnoses in the health area.

Eduarda Cabral, Universidade Prof. Antonio Edson Velano

I am a Biomedicine student, currently in my 7th semester at Professor Edson Antônio Velano University. I have a special interest in the areas of clinical analysis, microbiology and scientific research. Throughout my undergraduate studies, I have been developing technical skills in the laboratory, such as collecting and analyzing biological samples, and participating in projects that expand my knowledge about the physiological and pathological processes of the human body. I am constantly seeking new opportunities to learn and contribute to the promotion of health and the advancement of biomedical science.

Alessandra Cristina Pupin Silvério, Universidade Prof. Antonio Edson Velano

She holds a degree in pharmacy-biochemistry from the Federal University of Alfenas (1995), a master's degree in Biological Sciences from the Federal University of Alfenas (1999) and a PhD in Pharmaceutical Sciences from the Federal University of Alfenas (2016). She is currently a full-time professor at the JOSÉ DO ROSÁRIO VELANO UNIVERSITY. She has experience in the area of ​​Pharmacy as a teacher and researcher, with an emphasis on toxicological evaluation and analysis, working mainly on the following topics: rural worker, intoxication, carboxyhemoglobin, anticholinesterases and blood bag. Experience as a teacher and researcher in Medicine with an emphasis on medical biochemistry, diabetes and public health, Professor in the courses of Medicine, Pharmacy, Biomedicine, nutrition and physical education. Coordinator of the Planting and Harvesting Health Project responsible for the health of rural workers in the Health region of Alfenas and Guaxupé - south of Minas Gerais. Coordinator of the Public Health Research group at UNIFENAS. MEMBER OF THE BOARD AND STRUCTURING TEACHING TEAM OF THE PHARMACY COURSE - MEMBER OF THE STRUCTURING TEACHING TEAM OF THE BIOMEDICINE COURSE - MEMBER OF THE HUMAN RESEARCH ETHICS COMMITTEE - CONEP OF THE JOSÉ DO ROSÁRIO VELANO UNIVERSITY and MEMBER OF CONSUNI - UNIVERSITY COUNCIL - JOSÉ DO ROSÁRIO VELLANO UNIVERSITY.

References

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016 Nov;13(11):674–90. doi:10.1038/nrclinonc.2016.66. DOI: https://doi.org/10.1038/nrclinonc.2016.66

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018 Nov 29;379(22):2108–21. doi:10.1056/NEJMoa1809615. DOI: https://doi.org/10.1056/NEJMoa1809615

Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with immune cell enrichment. J Clin Oncol. 2019;37(15_suppl):1012–1012. doi:10.1200/JCO.2019.37.15_suppl.1012. DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.1012

Schmid P, Cortes J, Dent R, Pusztai L, McArthur HL, Kümmel S, et al. Event-free Survival With Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651. DOI: https://doi.org/10.1056/NEJMoa2112651

Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016 Jul 20;34(21):2460–7. doi:10.1200/JCO.2015.64.8931. DOI: https://doi.org/10.1200/JCO.2015.64.8931

Downloads

Published

2025-10-23

How to Cite

Ferreira, A., Cabral, E., & Pupin Silvério, A. C. (2025). TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER WITH PEMBROLIZUMAB: AN INTEGRATIVE REVIEW: UMA REVISÃO INTEGRATIVA. Mário Penna Journal, 2(2), 42–52. https://doi.org/10.61229/mpj.v2i2.65

Issue

Vol. 2 No. 2 (2024): Mário Penna Journal

Section

Artigos

License

Copyright (c) 2025 Mário Penna Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Autores que publicam nesta revista concordam com os seguintes termos:

  • Declaro que o presente artigo é original, não tendo sido submetido à publicação em qualquer outro periódico nacional ou internacional, quer seja em parte ou em sua totalidade.
  • Declaro, ainda, que uma vez publicado na revista Mário Penna Journal, editada pelo Instituto Mário Penna, o mesmo jamais será submetido por mim ou por qualquer um dos demais co-autores, caso haja, a qualquer outro periódico.
  • Por meio deste instrumento, em meu nome e em nome dos demais co-autores, porventura existentes, cedo os direitos autorais do referido artigo ao Instituto Mário Penna e declaro estar ciente de que a não observância deste compromisso submeterá o infrator a sanções e penas previstas na Lei de Proteção de Direitos Autorias (Nº9609, de 19/02/98).

Ficheiro:Cc-by-nc-sa icon.svg – Wikipédia, a enciclopédia livre

A Revista Mário Penna Journal é licenciada sob uma licença Creative Commons Atribuição-NãoComercial-CompartilhaIgual 4.0 Internacional